Fibroblasts are polymorphic cells with pleiotropic roles in organ morphogenesis, tissue homeostasis and immune responses. In fibrotic diseases, fibroblasts synthesize abundant amounts of extracellular matrix, which induces scarring and organ failure. By contrast, a hallmark feature of fibroblasts in arthritis is degradation of the extracellular matrix because of the release of metalloproteinases and degrading enzymes, and subsequent tissue destruction. The mechanisms that drive these functionally opposing pro-fibrotic and pro-inflammatory phenotypes of fibroblasts remain unknown. Here we identify the transcription factor PU.1 as an essential regulator of the pro-fibrotic gene expression program. The interplay between transcriptional and post-transcriptional mechanisms that normally control the expression of PU.1 expression is perturbed in various fibrotic diseases, resulting in the upregulation of PU.1, induction of fibrosisassociated gene sets and a phenotypic switch in extracellular matrix-producing pro-fibrotic fibroblasts. By contrast, pharmacological and genetic inactivation of PU.1 disrupts the fibrotic network and enables reprogramming of fibrotic fibroblasts into resting fibroblasts, leading to regression of fibrosis in several organs.
Fibroblasts play an important part in the maintenance of tissue integrity 1, 2 . They are also critical during the response to tissue injury, which goes far beyond the deposition of extracellular matrix. In the context of inflammatory and neoplastic diseases 2,3 , fibroblasts can differentiate into an extracellular matrix-producing contractile phenotype that promotes progressive accumulation of extracellular matrix and the initiation of fibrotic disease [4] [5] [6] . By contrast, in chronic inflammatory diseases, such as rheumatoid arthritis, fibroblasts acquire an extracellular matrix-degrading catabolic phenotype 7 . Phenotypic differences between extracellular matrix-producing pro-fibrotic fibroblasts and catabolic pro-inflammatory fibroblasts also become evident with respect to their distribution in tissues: pro-inflammatory fibroblasts display an imprinted phenotype that forms hypertrophic lining layers in tissues such as the joints and grow in a similar manner to locally invasive tumours. By contrast, pro-fibrotic fibroblasts do not form such lining layers, and instead establish a diffuse arrangement within the connective tissues [8] [9] [10] [11] .
Studying the transcriptional network that drives the polarization of fibroblasts into these two functionally opposing phenotypes revealed that PU.1, a transcription factor that belongs to the E26 transformation-specific (ETS) family, is highly expressed in extracellular matrix-producing fibrotic fibroblasts, but is silenced by epigenetic mechanisms in resting and extracellular matrix-degrading inflammatory fibroblasts. PU.1 activity therefore acts as a genetic switch that promotes the extracellular matrix-producing fibrotic fibroblast fate.
Fibrotic fibroblasts express PU.1
To understand the transcriptional network that induces the profibrotic phenotype of fibroblasts, we extracted promoter sequences of differentially expressed genes from a published database of skin biopsy specimens from patients with systemic sclerosis compared to unaffected control subjects 12 . These promoter sequences were searched for the occurrence of motifs of 984 human transcription factors 13 using the HOMER software. For each of the selected motifs, the correlation between the occurrence of the motif in the gene promoter and the respective differential expression level in fibrotic tissues was examined in comparison to healthy samples. Analysis of variance (ANOVA) highlighted 58 transcription factors with an increased presence in the regulatory sequences of pro-fibrotic genes (Fig. 1a) . A considerable proportion of those transcription factors belonged to the ETS family (17.2%). Of those ETS members, PU.1 showed the highest enrichment at promoters of pro-fibrotic genes.
PU.1 is a key factor in the differentiation of monocytes and B cells, and deregulation of PU.1 expression has been implicated as a central mechanism in the pathogenesis of leukaemia 14, 15 . In fibrotic diseases, however, we observed prominent expression of PU.1 in prolyl Article reSeArcH 4-hydroxylase (P4H)β + fibroblasts that lacked the haematopoietic fate markers CD45 and CD11b (Fig. 1b-g and Extended Data Fig. 1a, b ). PU.1 was upregulated in fibroblasts of various fibrotic diseases. We also detected PU.1-expressing lymphocytes; however, staining with additional fibroblast markers [16] [17] [18] [19] revealed that the majority of PU.1 + cells in fibrotic tissues were indeed fibroblasts ( Fig. 1b-g and Extended Data Fig. 1b-d) . In contrast to the abundant expression of PU.1 in fibrotic tissues, PU.1 + fibroblasts were not found in normal or inflamed tissues of the skin, lung, liver, kidney and joints ( Fig. 1b-g and Extended Data Fig. 1a , c, e).
PU.1 controls tissue fibrosis
To examine the physiological relevance of PU.1 expression in fibroblasts we used CRISPR-Cas9 technology to knock out the gene encoding PU.1 (in human, SPI1; in mouse, Spi1) in human fibroblasts isolated from fibrotic tissue. SPI1 knockout fibrotic fibroblasts displayed reduced collagen release, and expression of α-smooth muscle actin (α-SMA) and F-actin was similar to the expression levels in resting fibroblasts without affecting cell viability ( Fig. 2a and Extended Data Fig. 1f ). Conversely, PU.1 overexpression in human resting fibroblasts induced the transition of resting fibroblasts from healthy donors to a highly activated, pro-fibrotic phenotype with upregulation of collagen release, α-SMA and F-actin ( Fig. 2b and Extended Data Fig. 1g ). Next, we addressed the functional effect of PU.1-expressing fibroblasts in several mouse models of fibrosis that resembled different fibrotic conditions across different organs 20 . Similar to humans, PU.1 was expressed in fibroblasts from mouse models of fibrosis, but not in the non-fibrotic controls (Extended Data Figs. 2a-g, 3a-j). Fibroblast-specific knockout of Spi1 ameliorated fibrosis in these models ( Fig. 2c-f , Extended Data Fig. 1h -k).
Mechanisms that control PU.1 expression
Because PU.1 is required for tissue fibrosis, we next examined the potential mechanisms that could account for its differential expression between fibrotic and inflammatory fibroblasts. Inflammatory stimulisuch as tumour necrosis factor (TNF)-did not influence PU.1 expression in resting, fibrotic or inflammatory fibroblasts (Extended Data Fig. 4a ). Similarly, short-term stimulation with pro-fibrotic mediatorssuch as transforming growth factor (TGF)-β-did not convert resting or inflammatory fibroblasts into PU.1-expressing fibroblasts (Extended Data Fig. 4b ). Persistent TGF-β activity, as found in fibrotic diseases [21] [22] [23] , also failed to induce PU.1 in resting or inflammatory fibroblasts (Extended Data Fig. 4c ). In fibrotic fibroblasts, however, the basal levels of PU.1 were further upregulated by TGF-β in a 12 from patients with systemic sclerosis (n = 61) compared to unaffected controls (n = 36) using HOMER findMotifs. The fold change in expression of differentially expressed genes (log 2 (expression ratio)) was calculated and a linear model with the formula log 2 (expression ratio) ∝ MotifOccurrences was generated. Transcription factors are shown that had significantly increased motif occurrence (−log 10 (P)) on pro-fibrotic genes as assessed by ANOVA. b, d-f, Representative immunofluorescence images obtained using wide-field (b, e, f) and confocal (d) microscopy of human skin, lung, liver and kidney biopsy specimens stained for PU.1 (red), CD45 or P4Hβ (green) and with DAPI (blue); tissues were obtained from healthy individuals (n = 5 per tissue type), patients with systemic sclerosis (n = 25), plaque psoriasis (n = 7), idiopathic pulmonary fibrosis (n = 4), acute asthma (n = 5), alcoholic liver cirrhosis (n = 4), autoimmune hepatitis (n = 4), cirrhotic kidney (n = 4) and interstitial nephritis (n = 5). Haematoxylin and eosin (H&E)-stained tissue specimens are included. c, Semi-quantification of PU.1 + fibroblasts/total P4Hβ + fibroblasts per high-power field (HPF). e, Voronoi mesh-based tessellated pictures amenable to computational simulation, immunofluorescence microscopy images and histograms of respective immunofluorescence signals. g, Semi-quantification of PU.1 + fibroblasts per HPF. Six randomly chosen HPFs of each slide (n numbers are indicated in the legend for b-f) were used. Data are mean ± s.e.m. of biologically independent samples. P values were determined by one-way ANOVA with Tukey's multiple comparison post hoc test. NS, not significant. Fig. 4d, e ). Fibrotic fibroblasts maintained constant levels of PU.1 through several passages, in contrast with normal and inflammatory fibroblasts (Extended Data Fig. 4f ).
SMAD3-dependent manner (Extended Data
Because PU.1 expression was maintained in cell culture over multiple passages, we considered whether epigenetic mechanisms had a major role in its regulation 24, 25 . Differences in epigenetic programming have previously been related to the development of fibrotic diseases 24, 26 . Therefore, we analysed the epigenetic signatures of the SPI1 locus ( Fig. 3a ) in human resting, fibrotic and inflammatory fibroblasts. Although DNA methylation has been shown to have a central role in fibroblast activation 27,28 , we did not observe any major differences in DNA methylation at the SPI1 promoter and enhancer regions among fibroblast phenotypes (Fig. 3b ). However, the promoter and the −17 kb upstream regulatory element (URE) of the SPI1 locus were dominated by the presence of repressive histone 3 lysine 9 trimethylation (H3K9me3) and H3K27me3 in resting fibroblasts. This finding is consistent with increased expression levels of the H3K27 trimethyltransferase enhancer of zeste homologue 2 (EZH2) 29 (Fig. 3c and Extended Data Fig. 4g ). Resting fibroblasts showed a poised −17 kb URE (H3K4me1 and H3K27me3), which became active in fibrotic and inflammatory fibroblasts through co-localized H3K27 acetylation ( Fig. 3c ). Exposure to GSK126 30 , an inhibitor of EZH2 methyltransferase activity, induced expression of PU.1 in resting fibroblasts ( Fig. 3d and Extended Data Fig. 4h , i). By contrast, and consistent with the absence of H3K27me3 marks, incubation with GSK126 did not further increase PU.1 expression in fibrotic fibroblasts. In inflammatory fibroblasts, however, the repressive marks H3K9me3 and H3K27me3 were absent, but this was not sufficient for detectable amounts of PU.1 protein ( Fig. 3c, d ). We observed transcriptional activity at the SPI1 locus and detectable SPI1 mRNA levels ( Fig. 3e ), suggesting that post-transcriptional regulation might prevent the translation of PU.1 in inflammatory fibroblasts. microRNAs (miRNAs) regulate fibroblast growth and activation 10 . We identified seven potential miRNAs with conserved SPI1-binding sites ( Fig. 3f ) and found that miR-155 was significantly upregulated in inflammatory fibroblasts compared with resting and fibrotic fibroblasts, consistent with previous reports 31, 32 ( Fig. 3g ). As in B cells 33 , inactivation of miR-155 by antagomirs ( Fig. 3h and Extended Data Fig. 4j , k) induced expression of PU.1 in inflammatory fibroblasts ( Fig. 3i ), suggesting that SPI1 in inflammatory fibroblasts was post-transcriptionally regulated by miR-155. However, PU.1 might be degraded by another factor, and protein expression might have been restored because the expression of PU.1 was further increased by inhibition of miR-155. Therefore, we analysed SPI1 mRNA levels during inhibition of miR-155. We detected stable expression levels of SPI1 mRNA in miR-155-inhibited cells compared with cells transfected with scrambled antagomirs, indicating that it was unlikely that PU.1 was regulated by an independent factor that was affected by miR-155 ( Fig. 3j ). Together, these findings suggest that two independent mechanisms regulate PU.1 expression in fibroblasts at the level of transcription and translation, determining the functional state of these cells.
PU.1 induces polarization in fibrotic fibroblasts
Next, we analysed the molecular mechanisms of PU.1-induced fibroblast polarization. Chromatin immunoprecipitation (ChIP) analysis showed that PU.1 binds to the promoters of pro-fibrotic genes, such as ACTA2 and COL1A1 (Fig. 4a ). Similar to other ETS proteins, PU.1 binds to DNA sites that contain a 5′-GGAA-3′ core consensus sequence 34 . However, in contrast to other ETS transcription factors, PU.1 is strongly selective for binding sites in which the 5′-GGAA-3′ core is flanked by upstream AT-rich flanking sequences 34 . DB1976 35, 36 is a heterocyclic diamidine that competitively blocks PU.1 binding to DNA with minimal effects on other ETS transcription factors because of the high specificity of PU.1 for AT-rich flanking sequences of the 5′-GGAA-3′ core (Fig. 4b ). DB1976 decreased the transcription of COL1A1, reduced the expression of type I collagen and α-SMA and inhibited the expression of F-actin in fibrotic fibroblasts at least to the levels of resting fibroblasts at non-toxic concentrations ( Fig. 4c -e and Extended Data Fig. 4l , m). RNA-sequencing (RNA-seq) analysis and subsequent gene set enrichment analysis (GSEA) demonstrated that incubation with DB1976 inhibited the pro-fibrotic gene signature of fibrotic fibroblasts [37] [38] [39] [40] [41] [42] without effects on apoptosis-related and inflammatory Gene Ontology (GO)-defined gene sets ( Fig. 4f -i). DB1976 induced a gene expression pattern comparable to that of resting fibroblasts ( Fig. 4j ). Conversely, GSEA of resting fibroblasts cotransfected with SPI1 revealed upregulation of the pro-fibrotic gene set and no effects on apoptosis-related, inflammatory or monocyte gene sets ( Fig. 4k and Extended Data Fig. 5a ). Additional treatment with DB1976 completely blocked the pro-fibrotic effects of PU.1 overexpression (Extended Data Fig. 5b ). In three-dimensional full-thickness skin organoids, overexpression of PU.1 in resting fibroblasts increased the expression of collagen and α-SMA, as well as increasing the thickening of the skin organoid ( Fig. 4l ). RNA-seq data were validated using an integrative analysis that compared RNA-seq and PU.1 ChIP followed by sequencing (ChIP-seq) data. In total 1,247 genes (8.1% of all expressed genes) were found to be significantly differentially expressed between untreated fibrotic fibroblasts and fibrotic fibroblasts treated with DB1976 (q < 0.05). A significant majority of differentially expressed genes (n = 989; 79.3%) was associated with a PU.1 ChIP-seq peak. In addition to promoter regions, we also identified a substantial number of PU.1-binding sites in distal regions that were more than 50 kb away from known or predicted transcription start sites, reflecting the ability of PU.1 to control transcription through distal enhancers (Extended Data Fig. 5c ). To address the question of whether those PU.1-binding regions were associated with the regulation of the respective genes, several ENCODE datasets comprising DNase-seq and histone 
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ChIP-seq data were used for the unbiased identification of active regulatory elements within the respective genes. PU.1 ChIP-seq peaks at various q-value thresholds showed a marked overlap with these predicted active regulatory elements (Extended Data Fig. 5d ). These results underpin the regulatory function of PU.1 within fibrotic genes.
PU.1 switches inflammatory to fibrotic fibroblasts
We next investigated whether forced expression of PU.1 could repolarize inflammatory into fibrotic fibroblasts. Indeed, ectopic PU.1 expression in inflammatory fibroblasts resulted in the upregulation of fibrosis-associated genes instead of genes for extracellular matrixdegrading proteins and inflammatory mediators (Extended Data Fig. 5e ). In three-dimensional micro-mass organoids that resembled the synovial membrane, inflammatory fibroblasts showed a reduced ability to form lining layers after PU.1 overexpression (Extended Data Fig. 5f ). Instead, inflammatory fibroblasts that were forced to express PU.1 acquired an extracellular matrix-producing, pro-fibrotic phenotype that showed expression of α-SMA, increased collagen deposition and thickening of the dermal compartment in full-thickness skin organoids (Extended Data Fig. 5g ). Inhibition of miR-155 induced PU.1 expression in inflammatory fibroblasts and ingenuity pathway analysis revealed that the transcriptional network of miR-155 included several inflammatory targets such as NF-κB, in addition to fibrosis-related targets (data not shown). Accordingly, inhibition of miR-155 alone was not sufficient to induce a fibrotic phenotype in inflammatory fibroblasts (Extended Data Fig. 5h ). Consistent with the broader effects of miR-155, simultaneous blockade of miR-155 and PU.1 inhibited transcription of pro-fibrotic genes and induced expression of inflammatory mediators and metalloproteinases (Extended Data Fig. 5h ). These results highlight that fibrotic and inflammatory mediators are tightly balanced by a complex network of transcriptional and post-transcriptional factors. Within this network, PU.1 inhibition is sufficient to block transcription of fibrotic gene clusters.
PU.1 anchors differentiation towards fibrotic fibroblasts
Previously published reports show that PU.1 collaboratively interacts with other transcription factors at closely spaced binding sites to shape the phenotype of a cell 43 . To address whether PU.1 alone is sufficient to induce a fibrotic phenotype, we performed ChIP-seq and additionally investigated transcription factor binding in the vicinity of occupied PU.1 sites. We identified binding motifs for several pro-fibrotic factors, including TEAD1, CENP-B, B-MYB, SNAI2, MEF2D, SMAD3 and C/EBP, in the vicinity of PU.1 peaks. Notably, this represents a different set of factors from those known to collaboratively interact with PU.1 in monocytes and B cells 44 (Fig. 4m ). TEAD1 was further validated and showed robust expression levels in resting, fibrotic and inflammatory fibroblasts (Extended Data Fig. 6a ). Key pro-fibrotic genes were screened for PU.1 ChIP-seq peaks and potential flanking TEAD1-binding sites. ChIP analysis revealed binding of TEAD1 to predicted regions in key pro-fibrotic genes including HTR2B, ACTA2, COL1A1, COL1A2, CTGF (also known as CCN2), ITGAV, LPAR3, PDGFC, THBS1 and TGFB1 (Extended Data Fig. 6b ).
To confirm the necessity of the transcriptional network that includes PU.1 to induce a fibrotic phenotype, PU.1-transfected inflammatory fibroblasts were cultured under neutral, fibrotic and inflammatory conditions. As expected, PU.1 induced pro-fibrotic mediators in inflammatory fibroblasts cultured under neutral conditions. However, the expression of key fibrotic factors was substantially facilitated by TGF-β-related, fibrotic culture conditions. By contrast, TNF-rich, inflammatory conditions interfered with the fibrotic effects of PU.1 (Extended Data Fig. 6c ). These results corroborate the coordinating role of PU.1 as a susceptibility anchor within the network of factors that drives the differentiation towards a fibrotic phenotype.
Inhibition of PU.1 controls tissue fibrosis
Finally, we investigated pharmacological targeting of PU.1 as a potential strategy to prevent uncontrolled fibrotic tissue remodelling. DB1976 showed anti-fibrotic effects in vivo in various fibrosis models and across several organs. Treatment with DB1976 not only prevented bleomycin-mediated skin fibrosis, but also induced regression of pre-established fibrosis (Extended Data Fig. 7a-d ). Treatment with DB1976 in anti-fibrotic concentrations did not affect body weight, pain and distress levels of mice (Extended Data Fig. 7e, f) . At the cellular level, we did not detect disturbance of haematopoiesis, alterations in haematopoietic and mesenchymal stem cells, defects in B cell development in the bone marrow or T cell maturation within the thymus after DB1976 treatment (Extended Data Fig. 8a-j) . 14, 15 and determines the fate of respective progenitors [45] [46] [47] [48] . We found that the majority of PU.1expressing cells in fibrotic tissues, in multiple disease settings, are of a mesenchymal phenotype. PU.1 polarized resting fibroblasts and even repolarized extracellular matrix-degrading inflammatory fibroblasts to an extracellular matrix-producing fibrotic phenotype. PU.1 is associated with a network of pro-fibrotic factors including members of the TEAD-HIPPO, canonical TGF-β-SMAD and AP1 signalling pathways. Other transcription factors with fibrotic abilities, such as SNAI2 and myocyte enhancer factor (MEF) 2, bind in close vicinity to PU.1-binding sites within the genome and may contribute to the recruitment of the transcription machinery that drives the switch towards the fibrotic phenotype. Motif enrichment does not establish whether or not respective factors are required for collaborative binding. However, we show that the simultaneous induction of TGF-β-related mediators facilitates the pro-fibrotic properties of PU.1, whereas TNFrich, inflammatory settings interfere with PU.1. In line with previous reports in monocytes 43 , these results suggest that the crosstalk between PU.1 and factors that are enriched in the vicinity of PU.1 sites drive fibroblast polarization. Also analogous to its lineage-defining function in monocytes, our results demonstrate that PU.1 has a major coordinating role within this complex network of transcription factors in fibroblasts, as the inactivation of PU.1 alone is sufficient to prevent fibrotic polarization.
These findings also suggest that PU.1 inhibition may represent an effective therapeutic approach to treat a wide range of fibrotic diseases. Inactivation of PU.1 effectively reverted the fibrotic phenotype of fibroblasts to a resting state and induced the regression of tissue fibrosis. Furthermore, the level of PU.1 inhibition necessary to revert the functional phenotype of fibroblasts and alleviate fibrosis appears to be substantially lower than the one necessary for inhibition of haematopoietic cell differentiation. Targeting of PU.1 may thus provide a therapeutic option to not only efficiently but also safely interfere with excessive matrix deposition and enable the restoration of tissue homeostasis in fibrotic diseases.
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Ethical compliance and experimental approaches. This project complied with all relevant ethical regulations regarding animal research and human studies. Experiments were done in a blinded fashion except when specifically indicated. There were no exclusion criteria for the human and animal experiments. Mice were stratified according to sex and then randomized into the different groups. Cells from human donors were also randomized. Patient characteristics. Skin biopsies were obtained from 25 patients with systemic sclerosis according to the 2013 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria 52 , 7 patients with plaque psoriasis and 21 age-and sex-matched healthy volunteers. Lung tissue was obtained from 4 patients with idiopathic pulmonary fibrosis, 5 patients with asthma and 5 matched non-inflammatory/non-fibrotic controls. Liver samples were obtained from 4 patients with alcoholic liver cirrhosis 53 , 4 samples from patients with autoimmune hepatitis 54 and 5 matched non-inflammatory/non-fibrotic controls. To investigate fibrotic kidney tissue, we used cirrhotic kidneys from 4 patients with end-stage renal disease after renal transplantation or hydronephrosis. Kidney tissues from 5 patients with interstitial nephritis were used as controls. Normal kidney tissues were obtained from macroscopically normal portions of kidneys that had been surgically excised owing to the presence of a localized neoplasm (n = 5). Synovial tissue specimens were obtained from 5 patients with rheumatoid arthritis who fulfilled the 2010 ACR classification criteria for rheumatoid arthritis 55 as well as 5 patients with osteoarthritis. Normal synovium was used as control tissue, which was obtained from surgery specimens of patients with no articular disease (n = 4). Written informed consent was obtained from all subjects. The study was approved by the ethical committee of the University of Erlangen-Nürnberg. Mice. Wild-type C57/BL6NRj mice were purchased from Janvier. Spi1 fl/fl mice 46 were bred in-house. To selectively inactivate PU.1 in fibroblasts, Spi1 fl/fl mice were crossbred with either Col1a2 creER mice 56 or Col6 cre mice 57 to generate Spi1 fl/fl ;Co-l1a2 creER or Spi1 fl/fl ;Col6 cre mice, respectively. Cre-mediated recombination was induced by repeated intraperitoneal (i.p.) injections of tamoxifen over 5 days. Control groups were injected with corn oil. Spi1 GFP reporter mice 58 were provided by S.L.N. All mice were bred under specific pathogen-free conditions, and all studies were approved by the animal ethical committee of the government of Unterfranken, Wurzburg, Germany. The study has complied with all relevant ethical regulations. Cell culture. Human dermal fibroblasts were isolated from ten patients with systemic sclerosis (fibrotic fibroblasts) and ten age-and sex-matched healthy volunteers (resting fibroblasts). After enzymatic digestion of the skin biopsies with collagenase type II (Merck) for 3 h at 37 °C, the digested tissues were filtered using a 100-mm nylon filter and centrifuged at 1,400 r.p.m. for 5 min. The pellet was resuspended in DMEM/F12 medium containing 10% heat-inactivated fetal bovine serum (FBS), 25 mM HEPES, 100 U ml −1 penicillin, 100 μg ml −1 streptomycin, 2 mM l-glutamine, 2.5 μg ml −1 amphotericin B (Thermo Fisher Scientific) and 0.2 mM ascorbic acid (Sigma-Aldrich). Synovial fibroblasts (inflammatory fibroblasts) were isolated from inflamed joints of 6 patients with rheumatoid arthritis. Fibroblasts were cultured for three passages and then quality checked for a pure fibroblast population before use in experiments. Fibroblasts were negative for CD31, CD45, CD326 (also known as EpCAM) and KRT14 and positive for collagen-1, PDGFRα and vimentin. Representative FACS plots are presented in Extended Data Fig. 9a -c. Resting, fibrotic and inflammatory fibroblasts from passages 3-8 showed homogeneous characteristics with regard to proliferation, migration and invasion capacity (Extended Data Fig. 9d, e ) as assessed using a xCELLigence Real-Time Cell Analyzer (RTCA) instrument (ACEA Biosciences). As indicated, fibroblasts were transfected with 0.1 μg of either pUNO1 empty vector (control) or pUNO1-hSPI1a (both from InvivoGen) plasmids using the 4D-Nucleofector (Lonza). Gene silencing was achieved using either 3 μg control CRISPR-Cas9 plasmid or 3 μg of PU.1 CRISPR-Cas9 KO plasmid (h2) (Santa Cruz Biotechnology). miR-155 silencing was performed using the anti-hsa-miR-155-5p miScript miRNA inhibitor or the miScript negative control inhibitor (1,500 ng) (both from QIAGEN). In selective experiments, cells were incubated with recombinant TGF-β (5 ng ml −1 ) (PeproTech), recombinant human TNF (10 ng ml −1 ) (ImmunoTools) and/or a combination of one or both of the following: GSK126 (1 μM) (Selleck Chemicals) or DB1976 (2.5 μM; provided by D.W.B. and G.M.K.P.). Cell viability and cytotoxicity assays. Cell viability of cultured cells was quantified using the Cell Counting Kit (CCK)-8 (Dojindo Molecular Technologies) and an MRX ELISA reader (Dynex Technologies).
Preparation of micro-mass cultures.
Micro-mass organ culture experiments were performed as described elsewhere 9 . Synovial or dermal fibroblasts were released from the culture dish using TrypLE (Thermo Fisher Scientific) following transfection with plasmids as described above. Cells were resuspended in ice-cold Matrigel Matrix (BD Biosciences) at a density of 5 × 10 6 cells per ml. Then, 40-μl droplets of the cell suspension were placed onto non-adherent 12-well culture dishes (Thermo Fisher Scientific). Gelation was allowed for 45 min at 37 °C. Afterwards, the gel was overlaid with basal culture medium (DMEM, supplemented with penicillin, streptomycin, l-glutamine, nonessential amino acid solution, insulin-transferrinselenium (Thermo Fisher Scientific), 0.1 mmol l −1 of ascorbic acid, 10 ng ml −1 of TNF and 10% heat-inactivated FBS. The floating three-dimensional cultures were maintained for 3 weeks; the medium was changed twice a week. Three-dimensional full-thickness skin organoids. Three-dimensional fullthickness skin organoids were generated by submerging transfected fibroblasts (1 × 10 5 cells per ml) in neutralization solution (232.5 ml DMEM/F12, 7.5 ml FBS, 7.5 ml 3 M HEPES, 2.5 ml chondroitin sulfate, 10 mg ml −1 rat tail collagen type 1). This mixture (500 μl) was filled in cell-culture inserts with porous membranes (8 μm) and a 15-mm diameter providing a growth area of 1.13 cm 2 (Greiner Bio One). The dermal components were cultured for one day in DMEM supplemented with 10% FBS, 5 ng ml −1 TGF-β and 1% penicillin-streptomycin at 37 °C, 5% CO 2 and atmospheric O 2 . To build up full-thickness skin models, the epidermal component was generated by seeding 5 × 10 5 normal human epidermal keratinocytes resuspended in Epilife medium with 1% human keratinocyte growth supplement (E1 medium; Gibco) and with extra 1.44 mM CaCl 2 (denoted as E2 medium) on the apical surface of the dermal components on the following day. After a submersed incubation of the models in E2 medium for 16 h at 37 °C, 5% CO 2 and atmospheric O 2 , the medium was aspirated and the airlift-interface culture was initiated. Full-thickness skin models were cultured in E2 medium supplemented with 0.125 mM l-ascorbic acid 2-phosphate and 10 ng ml −1 keratinocyte growth factor (Sigma Aldrich) for an additional 5-10 days and the level of the culture medium was adjusted to the meniscus of the skin models 59 .
Real-time monitoring of cell proliferation, migration and invasion.
The realtime proliferation assay was performed using the xCELLigence RTCA system (ACEA Biosciences) according to the manufacturer's instructions. Cells were seeded at a density of 25% in an E-plate in cell-culture medium (10% FBS) and measured every hour for 7 days. As a negative control, serum-starved (0.1% FBS) medium was used. For assessment of cell migration and invasion, CIM-plates 16 were used according to the manufacturer's instructions. In brief, 2 × 10 4 cells were plated in serum-starved (0.1% FBS) medium in the upper chamber. The lower chambers were filled with cell-culture medium containing 10% FBS or with serum-starved medium as control. For invasion assays, the experimental setup of the migration assay was slightly modified as the upper chambers were loaded with 20 μl of a 1:10 dilution of Matrigel to create a three-dimensional biomatrix film in each well before cell loading. Cell status was measured by electrical impedance and the relative change between impedance measured at any time (t) and baseline; respective values are displayed as the dimensional parameter 'cell index' . The obtained data were analysed using the xCELLigence RTCA software. Results are presented as a curve over time.
Reporter assays. Human fibroblasts were transfected with a COL1A1 luciferase reporter plasmid (Active Motif) using the 4D-Nucleofector. Luciferase assays were performed using the Renilla Luciferase Assay System according to the manufacturer's instructions (Progema). Relative light units were obtained with a Luminoskan Ascent instrument with automated well-wise injection (Thermo Fisher Scientific). Relative light units were normalized to the protein concentration, as determined by a Bradford protein assay according to the manufacturer's protocol (Bio-Rad). Quantification of collagen proteins. The amount of soluble collagen in cellculture supernatants was quantified using the SirCol collagen assay (Biocolor). The total collagen content of tissue samples was determined by hydroxyproline assays 60 . Histological analysis. Formalin-fixed, paraffin-embedded skin sections (2-5 μm) were deparaffinized and stained with haematoxylin and eosin, Sirius red or trichrome. Dermal thickness was analysed at four different sites in each mouse in a blinded manner. For direct visualization of collagen fibres, Sirius red staining was performed (Sigma-Aldrich). For evaluation of lung tissue, the Ashcroft score was used as described elsewhere 61 . Liver cirrhosis evaluation (Scheuer score) was performed as described elsewhere 62 . Fluorescence imaging. Epitopes were retrieved from deparaffinized sections using a heat-induced method. In brief, sections were alternately bathed in boiling sodium citrate buffer (10 mM sodium citrate, pH 6.0) or Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween 20, pH 9.0). Each bathing step was repeated five times for 2 min following a washing step in distilled water for 5 min. For cryo-sections, tissues were placed in OCT compound (Tissue-Tek) (Newcomer Supply) and then snap-frozen in liquid nitrogen and cut to 7-μm slices. Sections were washed in distilled water after thawing and fixed in 4% PBS-buffered formaldehyde for 10 min following another washing step in PBS.
Next, sections were blocked for 1 h in PBS supplemented with 5% BSA and 2% horse serum. Primary antibodies were incubated overnight at 4 °C, secondary antibodies and DAPI after an intense washing step for 2 h at ambient temperature. Consecutive staining was performed to minimize cross-reactivity. Crossreactivity was blocked by pre-incubation with species-specific immunoglobulins. The following antibodies were used: α-SMA (1:500, clone 1A4, Sigma-Aldrich), cadherin-11 (1:100, polyclonal, LS-B2308, LS-Bio), CD45R/B220 (1:500, clone RA3-6B2, eBioscience), collagen I (1:200, clone COL1, Abcam), collagen I (1:500, polyclonal, ab21286, Abcam), CD11c (1:100, clone N418, Abcam), CD45 (1:500, polyclonal, ab10558, Abcam), F4/80 (1:200, polyclonal, ab100790, Abcam), F4/80 (1:100, clone CI:A3-1, Abcam), fibroblast activation protein (1:5,000, polyclonal, ab28244, Abcam), MRC2 (1:1,000, polyclonal, ab70132, Abcam), vimentin (1:500, clone VI-10, Abcam), CD3ε (1:100, clone 145-2C11), CD45-BV421 (1:500, clone 30-F11), CD49f-APC (1:1,000, clone GoH3), CD117-APC (1:1,000, clone 2B8), EpCAM-APC/Cy7 (1:1,000, clone G8.8), KRT14 (1:1,000, polyclonal, 905301) (all Biolegend), CD11b (1:100, clone M1/70), CD31 (1:20, polyclonal, AF3628), Ly6G/GR-1 (1:200, clone RB6-8C5) (all R&D Systems), PDGFRα-PE/Cy7 (1:100, clone APA5, Thermo Fisher Scientific), prolyl 4-hydroxylase subunit beta (1:50, clone 3-2B12, Acris), PU.1 (1:200, polyclonal, 2266, Cell Signaling) and vimentin-Alexa 647 (1:50, clone V9, Santa Cruz Biotechnology). As secondary antibodies for immunohistochemistry rabbit Alexa 594 (1:200, polyclonal, A-11037) , rabbit Alexa 488 (1:200, polyclonal, A-11034), rabbit Alexa 647 (1:500, polyclonal, A-21443), rat Alexa 647 (1:500, polyclonal, A-21472), mouse Alexa 488 (1:200, polyclonal, A11001), mouse Alexa 647 (1:500, polyclonal, A-21236) and goat Alexa 647 (1:500, polyclonal, A-21447) were used (all Thermo Fisher Scientific). As IgG controls for immunohistochemistry goat IgG (sc-2028), rabbit IgG (sc-2027), rat IgG (sc-2026) and mouse IgG (sc-2025) were used (all Santa Cruz Biotechnology). The specificity of the respective antibodies was confirmed by corresponding IgG staining (Extended Data Fig. 10a, b) . The F-actin cytoskeleton was visualized with rhodamine-conjugated phalloidin (1:250, R415, Thermo Fisher Scientific). In addition, cell nuclei were stained using DAPI (1:800, sc-3598, Santa Cruz Biotechnology). Six randomly chosen HPFs (0.125 mm 2 ) at 200-fold magnification per patient or healthy volunteer were evaluated by two experienced researchers in a blinded manner. Stained cells were visualized either using a Nikon Eclipse Ni-U microscope (Nikon) or an inverted CLSM-1P Leica SP5 II microscope (Leica). Representative images were reconstructed using the ImageJ distribution Fiji 63, 64 . Voronoi-tessellated pictures were generated as described elsewhere 65 . For quantification of F-actin, the same microscope settings were used for each HPF. The mean intensity of rhodamine-conjugated phalloidin was measured as raw integrated density (RawIntDen) divided by the area of the cell using ImageJ. Myofibroblasts were identified as single cells that were doublepositive for α-SMA and collagen and not directly adjacent to CD31 + endothelial cells (Extended Data Fig. 10c ); α-SMA and collagen double-positive cells were counted in three randomly chosen HPFs of n specimens per mouse in a blinded manner at 200-fold magnification. ChIP assays. ChIP assays were performed using the ChIP-IT Express Kit (Active Motif). In brief, 10 μg of sonificated chromatin extract was incubated with antibodies against H3K27me3, H3K27ac, H3K9me3, H3K4me1 and H3K4me3 (39155, 39297, 39161, 39135 and 39915; all from Active Motif), PU.1, SMAD3 (2266 and 9523; both from Cell Signaling Technology) and TEAD1 (610923 from BD Biosciences) or normal rabbit or mouse IgG antibody (sc-2027 X or sc-2025; both from Santa Cruz Biotechnology). Purification was performed using the Chromatin IP DNA Purification Kit (Active Motif) and bound sequences were determined by quantitative real-time PCR using primers listed in Supplementary  Table 1 . ChIP-seq. Single-end reads were generated from PU.1 precipitated (2266, Cell Signaling), input and IgG control DNA on an Illumina HiSeq 2500 system. Alignment to the GRCh37 reference genome was performed with bwa mem version 0.7.14-r1136 66 . MACS version 2.1.1.20160309 67 was used to call peaks for each sample, using both input and IgG alignments as controls. In preparation for a motif enrichment search, two different region files were generated from the peak files as output by MACS. First, a file with the union of all three peak files was generated. Second, a file with only the flanking regions (200 bp in either direction) of each peak region in the union file (vicinity analysis) was created. Motif enrichment analysis was then performed using HOMER software version 4.9.1 43 . For region of interest (ROI)-based ChIP-seq peak and RNA-seq overlap analysis, ROIs were defined as 225 kb upstream and downstream of differentially expressed genes 68 . Within each ROI, the most significantly enriched peak from ChIP-seq analysis was determined. Differentially expressed genes from RNA-seq were mapped to the annotation of PU.1 ChIP-seq peaks (q < 0.05). For the identification of active regulatory elements, 11 ENCODE datasets containing DNase-sequencing and histone ChIP-seq data of human dermal and lung fibroblast (ENCFF128ARX, ENCFF148DHA, ENCFF195SIN, ENCFF328XNN, ENCFF350PQN, ENCFF392WNX, ENCFF524YEK, ENCFF811YTI, ENCFF965XKX, ENCFF073ILZ and wgEncodeBroadHistoneNhlfH3k27acStdSig) were used. For each file, the 99th percentile of all enrichment values was set as the threshold. The regions beyond this threshold from all files were merged to determine the percentage of ChIP-seq peaks at various q-value thresholds overlapping these regions. RNA-seq. RNA-seq was performed on an Illumina HiSeq 2500 system with a read length of 100 bp (forward only). After adaptor trimming and filtering using cutadapt version 1.9.1 69 , reads were mapped to the Ensembl GRCh37 human reference using STAR version 2.5.2a 70 . Features were counted with subread feature-Counts version 1.5.1 71 (count > 5 as threshold) on the Ensembl GRCh37 release 85 genome annotation. All further analysis was performed in R version 2.15.3 using the DESeq2 package 72, 73 . GSEA was performed using GSEA version 3.0 software (Broad Institute) 51, 74 . The statistical significance was assessed using 10,000 random permutations of the gene set with a signal-to-noise metric for ranking genes. A FDR-corrected value of q < 0.25 was considered to be significant. Gene sets were obtained from the Molecular Signatures Database (MSigDB) version 6.1 or created based on published signature genes (fibrotic cluster). Bisulfite pyrosequencing. Genomic DNA was prepared from fibroblasts using the QIAamp DNA Blood Mini kit (QIAGEN). The DNA (1 μg) was bisulfite-modified using the EpiTect bisulfite kit (QIAGEN). PCR amplification of bisulfite-modified DNA (2 μl) was performed using AmpliTaq Gold polymerase (Thermo Fisher Scientific). The PCR program was 95 °C for 4 min; 5× 95 °C for 30 s, 52 °C for 90 s, 72 °C for 2 min; 25× 95 °C for 30 s, 52 °C for 90 s, 72 °C for 90 s; 72 °C for 4 min. The following primers were used: PU.1 promoter forward 5′-TAGTAAGTTAGGAGGGTAGTGGGTG-3′; biotin reverse 5′-CCCCATCCTAAAAAACTCTACATTA-3′; Pyro-seq forward 5′-GTTGGGTT GGTGGAGGAGT-3′; PU.1 enhancer forward 5′-GGTTGTAGTTGTTTTTG TTTTTATAT-3′; biotin reverse 5′-CTAAACATCCCCCTAAAACCTAAC-3′, Pyro-seq forward 5′-AGTTATTATAGGAAGTATGTG-3′. The PCR products were visualized with agarose gel electrophoresis. Afterwards, they were directly sequenced using the PyroMark Q48 Autoprep according to the manufacture instructions (QIAGEN). Cell isolation and flow cytometry. Mice were euthanized by cervical dislocation under anaesthesia and dissected to generate single-cell suspensions from the lung, spleen, thymus and/or bone marrow. Fat was thoroughly removed from the dissected organs and their capsules were opened to ensure good drainage of the digestive solution, which consisted of RPMI 1640 medium supplemented with 1 mg ml −1 collagenase D from Clostridium histolyticum and 0.2 mg ml −1 DNase I, grade II from bovine pancreas (both from Roche Diagnostics). For the digestion of liver and lung samples, the digestive solution was enriched with 0.1 mg ml −1 Dispase II (Roche Diagnostics). Lung, spleen and thymus were digested in 1 ml digestion medium at 37 °C for 1 h on a thermo shaker at 500 r.p.m. (Eppendorf). Pipetting every 20 min ensured good dissociation of the tissue. Tibias were cut off at both ends and bones were flushed with PBS to collect bone marrow. The resulting single-cell suspensions were filtered through 70-μm cell strainers and washed in a larger volume of RPMI 1640 supplemented with 10 mM EDTA and 10% FBS. Red blood cells were lysed after digestion by applying in-house-made ACK buffer for 1 min. Lysis was stopped by adding a sufficient amount of 10× PBS to generate a 1× solution. Cells were then washed in PBS supplemented with 5 mM EDTA and 2% FBS and filtered through 40-μm cell strainers. Skin and liver samples were centrifuged through a gradient to remove debris (Debris Removal Kit, Miltenyi Biotec). For flow cytometry analysis, 1 × 10 6 cells of the resulting single-cell suspensions were incubated in 100 μl of diluted antibody solution in V-shaped plates for 20 min on ice. The following antibodies were used: CD3ε-Pacific Blue or CD3ε-PE/Cy7 (1:500 or 1:100, respectively, clone 145-2C11), CD4-FITC (1:1,500, clone RM4-5), CD8a-APC (1:300, clone 53-6.7), CD11b-PE/Cy7 or CD11b-APC (each 1:1,000, clone M1/70), CD11c-PE/Cy7 or CD11c-APC/Cy7 (each 1:200, clone N418), CD25-PE or CD25-PE/Cy7 (each 1:500, clone PC61), CD29-PE (1:1,000, clone HMβ1-1), CD31-APC (1:1,000, clone WM59), CD31-PerCP/Cy5.5 (1:1,000, clone 390), CD34-PerCP/Cy5.5 (1:500, clone HM34), CD44-PE (1:2,000, clone IM7), CD45-BV421 (1:2,000, clone 30-F11), CD45-PerCP/Cy5.5 (1:1,000, clone HI30), CD45R/B220-FITC or CD45R/B220-APC/Cy7 (each 1:500, clone RA3-6B2), CD49f-APC (1:1,000, clone GoH3), CD115-PE (1:100, clone AFS98), CD117-APC or CD117-BV480 (each 1:100, clone 2B8), CD117-PE (1:500, clone 104D2), CD127/IL7R-PE/Cy7 (1:100, clone A7R34), EpCAM-APC/Cy7 (1:500, clone G8.8), EpCAM-FITC (1:200, clone 9C4), PDGFRα-PE (1:100, clone 16A1), PU.1-PE (1:1,000, clone 7C2C34), TER119-APC/Cy7 (1:100, clone TER119) (all Biolegend), CD45-V500 (1:1,000, clone 30F11), CD105-BV421 (1:100, clone MJ7/18) (all BD Biosciences), COL1A1-FITC (1:200, clone 5D8-G9, Merck), KRT14-PE (1:1,000, clone LL002, Novus Biologicals), PDGFRα-PE/Cy7 (1:1,000, clone APA5, eBiosciences) and vimentin-Alexa 647 (1:2,000, clone V9, Santa Cruz Biotechnology). For viability staining in flow cytometry Zombie Violet (1:1,000, 423113, Biolegend), DAPI (0.1 μg ml −1 , D9542, Sigma-Aldrich) and eFluor780 (1:4,000, 65-0865-14, eBiosciences) were used. Blocking of Fc receptors was performed before staining with fluorophore-labelled antibodies. Mouse blood (50 μl collected in EDTA) was incubated with the respective antibodies for 20 min at 4 °C. Afterwards, 450 μl of RBC Lysis/Fixation Buffer (1×) (Biolegend) was added for another 15 min at room temperature. After washing twice with PBS, cells were resuspended in PBS supplemented with 5 mM EDTA and 2% FBS and filtered through 40-μm cell strainers. All flow cytometry analyses were performed on a Gallios or Cytoflex-S flow cytometer (both Beckmann Coulter) equipped with 3 laser-(405 nm, 488 nm and 633 nm) and 10 fluorescence-detection channels and analysed using Kaluza version 1.5 (Beckmann) or CytExpert. Gating was performed as shown in Extended Data Fig. 8 . Gene-expression analysis. Total RNA was extracted from single-cell suspensions using either the Nucleo Spin RNA isolation kit (Macherey-Nagel) or the miRNeasy Mini Kit (QIAGEN). Subsequently, 1 μg of RNA was used to transcribe mRNA to cDNA following standard protocols. Real-time PCR was performed in triplicates using either the SYBR Select Master Mix (Thermo Fisher Scientific) or the miScript SYBR Green PCR Kit and miScript Primer Assay (both from QIAGEN) and a QuantStudio 6 Flex System (Thermo Fisher Scientific). Expression of target genes was calculated using the ΔC t comparative method for relative quantification after normalization. Samples without enzyme in the reverse-transcription reaction (non-RT controls) were used as negative controls. Unspecific signals caused by primer dimers were excluded by non-template controls and by dissociation curve analysis. Actb, let-7b or mir-15a were used to normalize for the amounts of cDNA within each sample. The following miScript primer assays were used: let-7b (MS00003122), miR-15a (MS00003178), miR-92a-2 (MS00032137), miR-155 (MS00031486), miR-326 (MS00003948), miR-580 (MS00010227), miR-6745 (MSC0075916), miR-6747 (MS00046515) and miR-6780a (MS00046872) (all from QIAGEN). Primer sequences are listed in Supplementary Table 1 .
In silico analysis of potential miRNA binding sites to SPI1. For predictions of potential miRNA binding to SPI1, miRWalk 49 , miRanda 75 and Targetscan 76 were used. The overlap of possible miRNAs from all three tools were further restricted to P < 0.0233 as well as SPI1 conserved binding sites predicted by miRWalk 49, 50 . Western blot analysis. Protein concentrations were determined using the Bradford protein assay according to the manufacturer's protocol (Bio-Rad). Equal amounts of protein were loaded on a Tris-glycine-buffered gel. Proteins were separated by SDS-PAGE and transferred to PVDF membrane. The membrane was incubated with the appropriate primary antibody and HRP-conjugated secondary antibodies (DAKO). The following antibodies were used: β-actin (1:10,000, clone A5441, Sigma-Aldrich), collagen I (1:1,000, clone COL-1, Abcam), TEAD1 (1:500, clone 610923, BD Biosciences), EZH2 (1:2,000, polyclonal, 4905), total histone H3 (1:1,000, polyclonal, 9715), tri-methyl-histone H3(Lys27) (1:1,000, polyclonal, 9733), total SMAD3 (1:1,000, polyclonal, 9513) or phospho-SMAD3 (1:1,000, polyclonal, 9520) and PU.1 polyclonal (1:500, 2266) (all Cell Signaling). As secondary antibodies in western blot anti-mouse (1:1,500, polyclonal, P0447) or anti-rabbit (1:2,000, polyclonal, P0448) HRP-conjugated secondary antibodies (all DAKO) were used. Blots were visualized using enhanced chemiluminescence (ECL). β-Actin was used as a loading control. Western blots were quantified using ImageJ Software (version 1.46r). Animal studies of fibrosis. The role of PU.1 in fibrosis was investigated in five different mouse models. Fibrosis was induced in 6-8-week-old littermates of the stated background. In the first model, bleomycin-induced skin fibrosis was induced by local injections of bleomycin at a concentration of 0.5 mg ml −1 in defined areas of 1 cm 2 at the upper back every other day for 4 weeks (6 weeks of age, mixed genders) 77 . Mice treated with subcutaneous injections of 0.9% NaCl were used as controls. Second, in the Tsk1 model (10 weeks of age, mixed genders), a dominant mutation in the gene that encodes fibrillin-1 results in activated TGF-β signalling in Tsk1 fibroblasts and progressive, generalized hypodermal thickening within 10 weeks after birth 70 . Third, bleomycin-induced pulmonary fibrosis was induced by a single intratracheal application of bleomycin (0.025 U, 8 weeks of age, males) using a high-pressure syringe (Penn-Century). Mice in which equal volumes of 0.9% NaCl were injected were used as a control 78 . Fourth, CCl 4 -induced hepatic fibrosis was induced by i.p. injections of CCl 4 diluted in sunflower oil (week 1: 1:31 dilution; week 2: 1:15 dilution; week 3: 1:7 dilution; week 4-6: 1:3 dilution) in mice (8 weeks of age, mixed genders) 79 three times per week. Sunflower oil was used in the control group. Fifth, an LP/J to C57BL/6 minor histocompatibility antigen-mismatched model, which reflects clinical and pathologic symptoms of human sclerodermatous chronic graft-versus-host disease, was used 80 . Recipient C57BL/6 mice underwent total body irradiation with a single dose of 9.5 Gy. Each recipient mouse received 5 × 10 7 splenocytes dissolved in 100 μl PBS within 6 h after irradiation from either C57BL/6 in a syngeneic or LP/J in an allogeneic, multiple minor mismatched transplantation via eye vein injection. As indicated, mice were treated with DB1976 81 . DB1976 was dissolved in water and applied i.p. Controls received NaCl. In the preventive model of bleomycin-induced skin fibrosis, DB1976 was injected i.p. simultaneously with bleomycin or NaCl applications for 4 weeks. In the therapeutic model of bleomycin-induced skin fibrosis, mice were prechallenged with bleomycin for 3 weeks to induce robust skin fibrosis. After 3 weeks, treatment with DB1976 or NaCl as control was initiated, while injections with bleomycin were continued. After a total of 6 weeks of bleomycin and 3 weeks of treatment with DB1976 or NaCl, mice were euthanized and the extent of fibrosis was compared to control mice. In the bleomycin-induced lung fibrosis model, DB1976 was injected for 4 weeks. In the model of CCl 4 -induced liver fibrosis, mice were treated for 6 weeks. ADVIA 120 analyser (version 3.1.8.0-MS; Siemens Healthcare Diagnostics) was used for the analysis of red blood cell counts, white blood cell count, thrombocytes and reticulocyte count. In all mouse experiments, body weight as well as pain and distress levels were monitored every second day. Pain and distress was evaluated as follows: 0, no signs of stress, mouse is active, in good condition, calm and has a normal appetite; 1, no/mild signs of stress, mouse is active but shows some signs of restlessness; 2, mild pain and distress, mouse is not well groomed, is slightly hunched and has a lower appetite; 3, moderate stress, mouse moves slowly and shows signs of depression; 4, severe pain, mouse loses substantial weight and is non-responsive to touch. If symptoms became worse, mice were excluded from the analysis and euthanized 82 . Statistical analysis. Results were visualized and analysed with Prism version 7 (GraphPad Software) and are depicted as the mean ± s.e.m. if not stated otherwise. For a two-group comparison, a Mann-Whitney U-test for nonparametric data was used. When two groups of samples were compared for iterating parameters or more than two groups of samples were compared, a one-way ANOVA was used. Tukey's range test was used as post hoc analysis of ANOVA. Significance levels are indicated as suggested by Prism Software: NS, P > 0.5, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq data used in this study have been deposited in the Gene Expression Omnibus (GEO) under the accession number GSE122334. The sequencing data from the ChIP-seq experiments have been submitted to the National Center for Biotechnology Information (NCBI) database under BioProject PRJNA480591; the project includes the following biosamples: SUB4300598, SUB4300595, SUB4300592, SUB4300591, SUB4300589, SUB4300587, SUB4300586, SUB4300583 and SUB4300579; the FASTQ data was uploaded to the NCBI Sequence Read Archive (SRA) under accession number SRP168244. 
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
